Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 2:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 33,017 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo/placebo Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

The Effect of Protein Supplementation on Bone Health in Healthy Older Men and Women

NCT00421408
View directory record Official record
Conditions
Bone Resorption, Osteoporosis
Interventions
Whey protein supplement, Placebo
Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
60 Years to 85 Years
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
2
States / cities
Farmington, Connecticut • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Oct 6, 2026, 2:17 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study With P2B001 in Subjects With Early Parkinson's

NCT03329508
View directory record Official record
Conditions
Parkinson Disease, Early Parkinson's Disease
Interventions
P2B001 0.6/0.75 mg, Rasagiline 0.75 mg, Pramipexole 0.6 mg, Marketed Pramipexole ER
Drug
Lead sponsor
Pharma Two B Ltd.
Industry
Eligibility
35 Years to 80 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
45
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 6, 2026, 2:17 PM EDT
Recruiting Phase 2 Interventional

A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain

NCT07641517
View directory record Official record
Conditions
Osteoarthritis, Knee, Chronic Pain
Interventions
LY4065967, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Palm Springs, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 6, 2026, 2:17 PM EDT
Completed Phase 3 Interventional Results available

Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.

NCT00286468
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Alogliptin and glyburide, Glyburide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
54
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 6, 2026, 2:17 PM EDT
Not listed Phase 2 Interventional

Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia

NCT02532218
View directory record Official record
Conditions
Hyperlipidemia
Interventions
ARI-3037MO
Drug
Lead sponsor
Arisaph Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
19
States / cities
Chino, California • Fort Lauderdale, Florida • Jacksonvile, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Oct 6, 2026, 2:17 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Radicle GI Health™ RFY: A Study Assessing the Impact of DAO Supplementation on Gastrointestinal and Other Histamine Intolerance Symptoms

NCT07835776
View directory record Official record
Conditions
GI Health
Interventions
Active GI Health Product 1, Placebo GI Health Control
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 105 Years
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 6, 2026, 2:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Probiotic Supplement and Microbiome, Immune System and Metabolic Syndrome

NCT03201068
View directory record Official record
Conditions
Metabolic Syndrome, Microbiome, Immune Function, Inflammation
Interventions
Probiotic supplement, Placebo
Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 6, 2026, 2:17 PM EDT
Terminated Phase 3 Interventional

Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis

NCT03710291
View directory record Official record
Conditions
Metabolic Acidosis, Chronic Kidney Disease
Interventions
TRC101, Placebo
Drug
Lead sponsor
Tricida, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
20
States / cities
Azusa, California • Denver, Colorado • Boca Raton, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 6, 2026, 2:17 PM EDT
Completed Phase 1 Interventional Results available

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

NCT05953740
View directory record Official record
Conditions
Schizophrenia
Interventions
MK-5720, Placebo to MK-5720, MK-8189, Placebo to MK-8189
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Glendale, California • Hallandale, Florida • Hollywood, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Oct 6, 2026, 2:17 PM EDT
Terminated Phase 1 Interventional

Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment

NCT02573740
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
ABT-957, Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
55 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Cypress, California • Orlando, Florida • The Villages, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Oct 6, 2026, 2:17 PM EDT
Terminated Phase 2 Interventional Results available

Simvastatin Augmentation of Lithium Treatment in Bipolar Depression

NCT01665950
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Simvastatin, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 6, 2026, 2:17 PM EDT
Completed Phase 3 Interventional Results available

Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)

NCT02580591
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
977 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
39
States / cities
Montgomery, Alabama • Concord, California • Fresno, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2018 · Synced Oct 6, 2026, 2:17 PM EDT
Completed Phase 2 Interventional Results available

Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder Population

NCT04932291
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
vafidemstat, Placebo
Drug
Lead sponsor
Oryzon Genomics S.A.
Industry
Eligibility
18 Years to 65 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
11
States / cities
Oceanside, California • Hialeah, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 6, 2026, 2:17 PM EDT
Terminated Phase 4 Interventional Results available

Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa

NCT00626574
View directory record Official record
Conditions
Subarachnoid Hemorrhage
Interventions
Epoetin alfa, Saline
Drug
Lead sponsor
University of South Florida
Other
Eligibility
30 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 6, 2026, 2:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Modafinil Effects on EEG Biomarkers of Reward and Motivation

NCT03616717
View directory record Official record
Conditions
Healthy Adults
Interventions
Modafinil, placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 35 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Oct 6, 2026, 2:17 PM EDT
Terminated Phase 2 Interventional

Dose Ranging Study of ART621 in Subjects Diagnosed With Rheumatoid Arthritis Taking Methotrexate

NCT00928317
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ART621, Placebo
Drug
Lead sponsor
Arana Therapeutics Ltd
Industry
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
6
States / cities
Tampa, Florida • Springfield, Illinois • Lincoln, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2010 · Synced Oct 6, 2026, 2:17 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation

NCT01862640
View directory record Official record
Conditions
Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
Interventions
Brexpiprazole, OPC-34712, Placebo Oral Tablet
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
55 Years to 90 Years
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
37
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Bellflower, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2020 · Synced Oct 6, 2026, 2:17 PM EDT
Not listed Not applicable Interventional

Study of External Neuromodulation to Improve Signs and Symptoms of Dry Eye in Visual Display Terminal Users

NCT04763018
View directory record Official record
Conditions
Visual Display Users With Previously Undiagnosed Dry Eye
Interventions
iTEAR100
Device
Lead sponsor
Olympic Ophthalmics, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 6, 2026, 2:17 PM EDT
Completed Phase 3 Interventional

Bioequipotency Study of Idrabiotaparinux and Idraparinux in Patients With Deep Venous Thrombosis of the Lower Limbs

NCT00311090
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Idrabiotaparinux sodium, Idraparinux sodium, Avidin, Placebo (for Avidin)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
757 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Oct 6, 2026, 2:17 PM EDT
Completed Not applicable Interventional

"A Clinical Study Investigating the Effectiveness of OTC Scar-management Modalities"

NCT04169490
View directory record Official record
Conditions
Scar, Keloid, Hypertrophic Scar, Cicatrix
Interventions
Placebo Cream Base Emulsion Moisturizer, FS2 Emulsion Moisturizer, Active Comparator Onion Skin Extract Gel (Mederma), Active Comparator Silicone Gel (Kelo-Cote), Active Comparator Silicone Gel (Kelo-Cote) + FS2 Emulsion Moisturizer
Other
Lead sponsor
The Center for Clinical and Cosmetic Research
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 6, 2026, 2:17 PM EDT
Recruiting Not applicable Interventional

Pain and Major Depressive Disorder

NCT04556890
View directory record Official record
Conditions
Major Depressive Disorder, Chronic Pain
Interventions
Active rTMS/Active iTBS DFPLC/Sham Pain M1, Active rTMS/Active iTBS
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 6, 2026, 2:17 PM EDT
Withdrawn Phase 2 Interventional

Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital

NCT06834997
View directory record Official record
Conditions
Endometriosis, Endometriosis Related Pain, Endometriosis, Pain
Interventions
Dronabinol Capsules, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Hosuton, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 6, 2026, 2:17 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

A Randomized, Double-Blind Study to Assess the Effect of a Postbiotic on Oxidative Stress and Exercise Performance

NCT06795425
View directory record Official record
Conditions
Oxidative Stress, Healthy, Exercise-induced Muscle Damage, Exercise-induced Muscle Soreness, Immune Function, Gut Health, Microbiome Analysis, Exercise Performance, Exercise Metabolism
Interventions
Postbiotic Active Lifestyle Blend, Placebo
Dietary Supplement · Other
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 6, 2026, 2:17 PM EDT
Completed Phase 2 Interventional

Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With ADHD

NCT00315276
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, ADHD
Interventions
Modafinil
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
18
States / cities
Little Rock, Arkansas • Lafayette, California • Northridge, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2012 · Synced Oct 6, 2026, 2:17 PM EDT